News | May 03, 2025
SMS Pharmaceuticals’ Vizag plant receives WHO Geneva prequalification
This significant milestone enhances our global regulatory standing
This significant milestone enhances our global regulatory standing
The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The supply of these goods is set to commence within the first quarter of FY26
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products
Subscribe To Our Newsletter & Stay Updated
